摘要
随着人类免疫缺陷病毒(HIV-1)感染在全球的蔓延及耐药株的出现,寻求有效的治疗方法成为当务之急。趋化因子受体5(Chemokine receptor 5,CCR5)是HIV-1侵入靶细胞的主要辅助受体之一。目前已发现许多CCR5拮抗剂,其中一些化合物已进入临床试验或应用;以CCR5为靶点的基因治疗亦取得了一定的进展。本综述以CCR5为靶点的药物和基因治疗两方面的研究进展进行总结。
Abstract. Along with the spread of human immunodeficiency virus 1 （HIV-1） infection in the world and the emergence of drug--resistant viral strains, it is urgent to seek the novel potent therapies. Chemokine receptor 5 （CCR5） is one of the main coreceptors involved in the entry of HIV-1 into target cells. Nowadays, a number of CCR5 antagonists have been developed and some of them have progressed to clinical trials or been approved. Research progress has also been made in the CCRS -- targeted gene therapy. This review summarizes the recent research progress on the CCRS-targeted drug and gene therapy.
出处
《病毒学报》
CAS
CSCD
北大核心
2014年第1期79-83,共5页
Chinese Journal of Virology
基金
东南大学教学改革研究项目(2010-079)
东南大学大学生科研训练项目(SRTP)(1210286093)
